Announcements Trials
Browse Landscape

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Conditions

Pain 4Breakthrough Cancer Pain 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Sezary Syndrome 1Sarcoma 1Quality of Life 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Ovarian Neoplasms 1Neuralgia 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Fentanyl 3Nasal Sprays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Breakthrough Cancer Pain × Fentanyl × Clear all
NCT03895762 2022-05-05

OASIS

A.Menarini Asia-Pacific Holdings Pte Ltd

Completed
143 enrolled

Breakthrough Cancer Pain

NCT01693328 2014-01-15

Qualipec

Archimedes Development Ltd

Unknown
300 enrolled

Breakthrough Cancer Pain

NCT01698645 2013-07-11

Qualipec

Archimedes Development Ltd

Unknown
150 enrolled

Breakthrough Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡